EL SEGUNDO, Calif., – Ten-year-old Healthcare Communications Group (HCG), a privately-held industry leader in pharmaceutical clinical trial patient recruitment, retention, and clinical operational efficiency for studies of pivotal compounds, has announced the expansion of its global operations. This includes the opening of two new offices, establishing enhanced global delivery alliances, and introducing a Web-based portal to facilitate worldwide trial communications.
“We are experiencing tremendous growth in our global operations,”
Global Delivery Alliances Formed
HCG points with pride to its record of consistently exceeding recruitment and retention enrollment goals for global clinical trials. Recently, HCG expanded its partnerships internationally to further its worldwide delivery of improved enrollment outcomes. This involved engaging five recruitment delivery providers, selected specialized sites, and several clinical thought leaders. These alliances enable HCG to leverage region-specific geographic therapeutic knowledge as well as cultural nuances to enhance patient recruitment results. The company now supports clinical enrollment in the BRIC countries (Brazil, Russia, India and China), Latin America, Asia, the Middle East, Nordic Countries, Central and Eastern Europe (CEE), and Western Europe. HCG’s international “turnkey”/one-
Scientific Advisory Team Announced
HCG also announced that it has partnered with Kate Zhong, MD, an internationally respected board-certified psychiatrist, to chair HCG’s Scientific Advisory Board. Dr. Zhong has more than 15 years of clinical and pharmaceutical experience, and has provided multifaceted services to industry and academic centers both in the U.S. and China during that time. Dr. Zhong will provide clinical oversight to support HCG’s global patient recruitment engagements.
“We are pleased to have someone as distinguished as Dr. Zhong as Chairman of our Scientific Advisory Board and clinical consultant partner," said Kilpatrick. "Her experience in neuroscience, specifically schizophrenia and Alzheimer’s disease, will be a valuable resource in enhancing our sponsors’ clinical trial recruitment effectiveness."
Global Technologies Initiated
To further enhance its extensive site-focused enrollment model with its sponsors, HCG is developing a global Web-based communications and tracking portal to strengthen communications between sites, pharmaceutical study staff teams, CROs, and HCG during trial engagements. This new technology will update enrollment metrics on a real-time basis, and enable sites to order materials and communicate with study staff and HCG via the Web 24 hours a day/7 days a week. The system provides for reduced time frames for customizations and shipment, while answering questions quickly and efficiently.
“HCG has a long-standing reputation for being the best at identifying strategies and implementing tactics that deliver high patient recruitment ROIs on U.S. clinical trials,” said Jeanne Meadow, Senior Vice President and Chief Operating Officer of HCG. “We are pleased that our profile is growing rapidly in alignment with our new business and global partnerships. Our operational plan for growth in 2009 includes opening offices in China and Latin America.”
